New product: Belantamab mafodotin (Blenrep) 100 mg powder for concentrate for solution for infusion

This is licensed as monotherapy for multiple myeloma in patients who have received ≥4 prior therapies, disease is refractory to ≥1 proteasome inhibitor, 1 immunomodulatory agent, and an anti-CD38 monoclonal antibody and have demonstrated disease progression on the last therapy.

Source:

electronic Medicines compendium